Amadeus FiRe AG
- WKN: 509310
- ISIN: DE0005093108
- Land: Deutschland
Nachricht vom 21.10.2021 | 06:57
Amadeus FiRe AG raises earnings forecast again
Amadeus FiRe AG / Key word(s): Change in Forecast/Quarterly / Interim Statement
Frankfurt/Main, October 21, 2021. Amadeus FiRe AG completed the first nine months of fiscal year 2021 with very positive operations. Significant increases in revenue and earnings were generated in both business segments, Personnel Services and Training. The pre-crisis level has already been clearly exceeded.
Group sales increased by 35.8 percent to EUR 274.8 million and operating profit from operating activities (operating EBITA) by around 75 percent to EUR 49.4 million. Earnings per share, based on the net profit for the period attributable to ordinary shareholders of the parent company, more than doubled to EUR 4.73 in the first nine months of 2021, compared to EUR 2.12 in the previous year.
The positive momentum of the first half-year continued even better than expected in the third quarter. After the Management Board had already significantly raised its earnings forecast at the half-year point to an increase in operating EBITA of at least 50 percent to more than EUR 60 million, the forecast is revised upwards once again. For the full year 2021 the Management Board expects to outperform the earnings threshold of EUR 65 million for operating EBITA.
Amadeus FiRe AG
|Company:||Amadeus FiRe AG|
|Hanauer Landstrasse 160|
|60314 Frankfurt am Main|
|Phone:||+49 (0)69 96876 - 180|
|Fax:||+49 (0)69 96876 - 182|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1242371|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
02. Dezember 08:25 Salesforce: Der Zahlen-Schock sitzt tief
02. Dezember 08:28 Volkswagen: Neuer Kurstreiber für die Aktie?!
02. Dezember 08:30 Zalando: Das macht jetzt Hoffnung
02. Dezember 08:30 Hot-Stock der Woche: Das Netflix fürs Kinderzimmer
02. Dezember 09:00 Auch das noch: Apple warnt vor nachlassender iPhone-Nachfrage
News im Fokus
Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025
01. Dezember 2021, 15:38
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: Bio-Gate AG (von GBC AG): Kaufen
02. Dezember 2021